The Right Tools to Manage and Monitor a Complex Process
Developing an effective antibody-drug conjugate (ADC) is never simple: First, you need to engineer antibodies with the proper affinity and specificity. Then you must conjugate an effective drug/cross-linker combination to the antibody. Finally, you need to determine the optimal number of drugs per antibody. This drug-to-antibody ratio is a critical quality attribute. You must carefully monitor it during the development process to ensure that your ADC produces the desired potency, minimizes off-target effects, and exhibits good pharmacokinetic properties. Agilent’s portfolio of solutions include liquid chromatography, LC/MS, and software suites.